Psychotic Disorders Treatment Development Program


This program supports studies of novel psychopharmacological and somatic approaches to alleviating the full spectrum of symptom domains found in patients with schizophrenia and schizophrenia spectrum disorders, including positive symptoms, deficit symptoms, disorganization, and cognitive deficits associated with these conditions. The program also supports studies that integrate investigations of the mechanisms of treatment response with efficacy of treatments, and studies designed to develop biomarkers and other predictors of treatment response for these conditions.

Areas of Emphasis


Mi Hillefors, M.D., Ph.D.
Program Chief
6001 Executive Boulevard, Room 7125; MSC 9632